NCT02549833View on ClinicalTrials.gov

Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 17, 2016

Primary Completion Date

August 15, 2022

Study Completion Date

August 31, 2024

Conditions
OligodendrogliomaAstrocytoma, Grade IIGlioma, AstrocyticGliomaMalignant GliomaOligoastrocytoma, Mixed
Interventions
BIOLOGICAL

GBM6-AD and poly-ICLC before and after surgery

Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination

BIOLOGICAL

GBM6-AD and poly-ICLC after surgery only

Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination

Trial Locations (1)

94143

University of California, San Francisco

All Listed Sponsors
collaborator

University of Minnesota

OTHER

lead

Jennie Taylor

OTHER

NCT02549833 - Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | Biotech Hunter | Biotech Hunter